Intangible Assets

12 Months Ended

Mar. 31, 2024

Intangible Assets, Net (Excluding Goodwill) [Abstract]

A reconciliation of the activity affecting intangible assets, net for each of 2024 and 2023 is as follows:


	Year Ended March 31, 2024
(In thousands)	Indefinite- Lived Tradenames		Finite-Lived Tradenames and Customer Relationships		Totals
Gross Carrying Amounts
Balance – March 31, 2023	$	2,168,902	$	411,118	$	2,580,020
Additions (a)	393		680		1,073



Effects of foreign currency exchange rates	(2,133)		(540)		(2,673)
Balance – March 31, 2024	$	2,167,162	$	411,258	$	2,578,420

Accumulated Amortization
Balance – March 31, 2023	$	—	$	238,127	$	238,127
Additions	—		19,784		19,784

Effects of foreign currency exchange rates	—		(74)		(74)
Balance – March 31, 2024	$	—	$	257,837	$	257,837

Intangible assets, net – March 31, 2024	$	2,167,162	$	153,421	$	2,320,583

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	2,092,853	$	135,932	$	2,228,785
International OTC Healthcare	74,309		17,489		91,798

Intangible assets, net – March 31, 2024	$	2,167,162	$	153,421	$	2,320,583

(a) On January 8, 2024, our Australian subsidiary acquired one of its suppliers. In connection with this acquisition, we preliminarily allocated $1.1 million to intangible assets.


	Year Ended March 31, 2023
(In thousands)	Indefinite- Lived Tradenames		Finite-Lived Tradenames and Customer Relationships		Totals
Gross Carrying Amounts
Balance – March 31, 2022	$	2,476,559	$	436,174	$	2,912,733



Tradename impairment	(298,664)		(22,748)		(321,412)
Effects of foreign currency exchange rates	(8,993)		(2,308)		(11,301)
Balance – March 31, 2023	$	2,168,902	$	411,118	$	2,580,020

Accumulated Amortization
Balance – March 31, 2022	$	—	$	216,098	$	216,098
Additions	—		22,266		22,266

Effects of foreign currency exchange rates	—		(237)		(237)
Balance – March 31, 2023	$	—	$	238,127	$	238,127

Intangible assets, net – March 31, 2023	$	2,168,902	$	172,991	$	2,341,893

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	2,092,852	$	154,552	$	2,247,404
International OTC Healthcare	76,050		18,439		94,489

Intangible assets, net – March 31, 2023	$	2,168,902	$	172,991	$	2,341,893

During the fourth quarter of each fiscal year, in conjunction with our strategic planning process, we perform our annual impairment analysis for intangible assets. We utilized the excess earnings method to estimate the fair value of our individual indefinite-lived intangible assets. The assumptions subject to significant uncertainties in the analysis include the discount rate, as well as future sales, gross margins and advertising and marketing expenses. The discount rate assumption may be influenced by such factors as changes in interest rates and rates of inflation, which can have an impact on the determination of fair value. Additionally, should the related fair values of intangible assets be adversely affected as a result of declining sales or margins caused by competition, changing consumer needs or preferences, technological advances, changes in advertising and marketing expenses, or the potential impacts of supply chain constraints, labor shortages, or inflation, we may be required to record additional impairment charges in the future.

At February 28, 2022, in conjunction with the annual test for impairment of intangible assets, we recorded an impairment charge of $0.7 million. In connection with our long-term planning, two non-core brands in our North American OTC Healthcare segment were discontinued and therefore the related finite-lived intangible assets were written off.

As a result of our annual impairment test at February 28, 2023, the fair values of three of our indefinite-lived intangible assets, Summer’s Eve, DenTek and TheraTears, did not exceed the carrying values and, as such, impairment charges totaling $298.7 million were recorded. The impairment charges were primarily a result of an overall increase in the discount rate used to value the brands, as well as, in the case of Summer’s Eve, our reassessment of the long-term sales projections of this brand during our annual planning cycle. The indefinite-lived intangible assets impaired are all part of our North American OTC Healthcare segment.

Our analysis at February 28, 2023 concluded that the fair value of several of our non-core finite-lived intangible assets did not exceed their carrying values, and as such, impairment charges of $22.7 million were recorded. The impairment charges were the result of our reassessment of the long-term sales projections for the associated non-core brands during our annual planning cycle, the largest of which pertains to the strategic exit of our DenTek private label business. The finite-lived trademarks impaired are all part of the North American OTC Healthcare segment.

At February 29, 2024, in conjunction with the annual test for impairment of intangible assets, the estimated fair value exceeded the carrying value for all intangible assets and accordingly, no impairment charge was taken.

Our analysis at February 29, 2024 determined that all indefinite-lived intangible assets had a fair value that exceeded their carrying value by at least 10%, with the exception of Summer’s Eve and TheraTears within our North American Women’s Health reporting unit and North American Eye & Ear Care reporting unit, respectively. We performed a sensitivity analysis of our weighted average cost of capital, and we determined that a 50-basis point increase in the weighted average cost of capital used to value all of our indefinite-lived intangible assets would have resulted in an impairment charge of $3.2 million. Additionally, a 50-basis point decrease in the terminal growth rate used for each of our indefinite-lived intangible assets would not have resulted in any of our indefinite-lived intangible assets' fair values being less than their carrying values.

The weighted average remaining life for finite-lived intangible assets at March 31, 2024 was approximately 7.7 years, and the amortization expense for the year ended March 31, 2024 was $19.8 million. At March 31, 2024, finite-lived intangible assets are expected to be amortized over their estimated useful lives, which ranges from a period of 10 to 24 years, and the estimated amortization expense for each of the five succeeding years and periods thereafter is as follows (in thousands):


(In thousands)
Year Ending March 31,	Amount
2025	$	18,139
2026	16,189
2027	14,597
2028	12,262
2029	12,262
Thereafter	79,972
	$	153,421